Drugs Containing Excipient (Inactive Ingredient) MAGNESIUM CARBONATE

Branded drugs containing MAGNESIUM CARBONATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	AROMASIN	exemestane	0009-7663	MAGNESIUM CARBONATE
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC	PREVACID	lansoprazole	0067-6286	MAGNESIUM CARBONATE
Parke-Davis Div of Pfizer Inc	ACCURETIC	quinapril hydrochloride and hydrochlorothiazide	0071-0222	MAGNESIUM CARBONATE
Parke-Davis Div of Pfizer Inc	ACCURETIC	quinapril hydrochloride and hydrochlorothiazide	0071-0223	MAGNESIUM CARBONATE

Generic drugs containing MAGNESIUM CARBONATE excipient

Company	Ingredient	NDC	Excipient
Pharmacia & Upjohn Company LLC	exemestane	0009-7663	MAGNESIUM CARBONATE
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC	lansoprazole	0067-6286	MAGNESIUM CARBONATE
Parke-Davis Div of Pfizer Inc	quinapril hydrochloride and hydrochlorothiazide	0071-0222	MAGNESIUM CARBONATE
Parke-Davis Div of Pfizer Inc	quinapril hydrochloride and hydrochlorothiazide	0071-0223	MAGNESIUM CARBONATE

Magnesium Carbonate Pharmaceutical Excipient Market: Dynamics, Financial Trajectory, Patents, and Supply Risk

Last updated: August 2, 2026

Magnesium carbonate is a mature, low-cost pharmaceutical excipient with limited product differentiation and no meaningful standalone patent exclusivity. Its commercial outlook depends on pharmaceutical-grade compliance, supply reliability, particle engineering, and the performance of downstream formulations rather than on novel-molecule economics. Demand is likely to grow at a low-single-digit rate, while pricing remains exposed to energy costs, mineral inputs, qualification requirements, and competition from magnesium oxide, magnesium hydroxide, calcium carbonate, and synthetic excipient systems.

Public companies do not report pharmaceutical-grade magnesium carbonate as a separate revenue category. Market estimates therefore rely on broader magnesium compounds, pharmaceutical excipients, and specialty minerals data rather than audited product-level financial statements.

What is magnesium carbonate used for in pharmaceutical manufacturing?

Magnesium carbonate is an inorganic magnesium salt used in oral solid dosage forms, antacid products, mineral supplements, powder formulations, and selected process applications. Its functions depend on grade, hydration state, particle size, density, and production method.

Pharmaceutical function	Commercial relevance
Magnesium source	Used in mineral supplements and combination products
Antacid ingredient	Neutralizes gastric acid in eligible formulations
Bulking agent	Adds mass to tablets, powders, and capsules
Absorbent	Used where moisture or oil absorption is required
Flow and processing aid	Supports powder handling in selected formulations
Carrier or diluent	Used in certain dry blends and oral dosage systems

Magnesium carbonate is commonly supplied as light or heavy grades. Light magnesium carbonate generally has lower bulk density and higher apparent volume. Heavy magnesium carbonate has greater bulk density and is selected where compactness, flow, or tablet-fill behavior is more important.

The relevant commercial specification is often not limited to chemical identity. Buyers evaluate assay, elemental impurities, loss on drying, microbiological quality, particle-size distribution, bulk density, tapped density, flowability, residual solvents, heavy metals, and batch-to-batch consistency.

How large is the pharmaceutical magnesium carbonate market?

No authoritative public source provides a separately audited global revenue figure for magnesium carbonate used as a pharmaceutical excipient. Available market reports generally combine magnesium carbonate with other magnesium compounds or place it within the broader pharmaceutical excipient market.

The market is best understood as a small specialty segment within three overlapping categories:

1. Pharmaceutical excipients.
2. Magnesium compounds.
3. Antacid and mineral-supplement ingredients.

This structure limits the reliability of top-down market estimates. A report covering the global magnesium compounds market may include refractory, agricultural, food, feed, water-treatment, and industrial applications. Those segments are substantially larger than pharmaceutical excipient demand and should not be treated as proxies for pharmaceutical-grade revenue.

What drives demand for pharmaceutical-grade magnesium carbonate?

Demand is linked to:

• Growth in generic oral solid dosage production.
• Expansion of over-the-counter antacid and digestive-health products.
• Magnesium supplementation and nutrition products.
• Outsourcing of tablet and capsule manufacturing.
• Increased use of direct-compression and engineered powder systems.
• Pharmaceutical production growth in Asia-Pacific, Latin America, and the Middle East.
• Regulatory replacement of poorly documented or inconsistent mineral sources.

The volume requirement per finished product is usually modest. As a result, magnesium carbonate is not a major cost component in most tablets. A buyer’s decision is more likely to depend on qualification, supply continuity, documentation, and processing performance than on a small unit-price difference.

What is the financial trajectory for magnesium carbonate excipients?

The financial trajectory is mature and volume-driven rather than innovation-driven. A reasonable base case is low-single-digit annual revenue growth in pharmaceutical applications, with higher growth possible in magnesium supplements and selected specialty powder systems.

Financial factor	Expected effect
Pharmaceutical volume growth	Positive, low to moderate
Generic-drug manufacturing	Positive
Commodity mineral competition	Negative for pricing
Energy and transportation costs	Negative for gross margin
Higher regulatory standards	Positive for qualified suppliers
Product differentiation	Limited but commercially important
Long-term contracts	Stabilize revenue and margins
Spot-market exposure	Increases price volatility
Regional supply concentration	Raises disruption risk
Premium pharmaceutical grades	Support higher margins

Revenue growth should not be confused with margin expansion. Magnesium carbonate is chemically simple and generally replaceable. Suppliers with only a basic commodity grade face pricing pressure. Suppliers that provide validated pharmaceutical grades, regulatory packages, stable particle-size distributions, and reliable global supply can obtain a premium.

A likely financial pattern is:

• Near term: input-cost and logistics volatility.
• Medium term: modest volume growth with selective price increases.
• Long term: stable demand, limited pricing power, and gradual migration toward higher-specification grades.

The strongest margins are likely to occur in qualified, low-bioburden, tightly controlled grades rather than in bulk industrial material.

Which companies supply pharmaceutical-grade magnesium carbonate?

The competitive landscape includes mineral producers, specialty chemical companies, pharmaceutical raw-material distributors, and excipient specialists. Public disclosures rarely isolate magnesium carbonate revenue.

Relevant supplier categories include:

Integrated mineral producers

These companies benefit from access to magnesite, brine, or other magnesium-bearing raw materials. Integration can reduce raw-material risk and support large-volume contracts. Their pharmaceutical exposure may remain small relative to industrial, agriculture, refractory, and environmental businesses.

Specialty pharmaceutical-material suppliers

These suppliers compete through:

• Pharmacopeial compliance.
• Documentation and change-control systems.
• Regulatory support.
• Global distribution.
• Small-batch and custom-grade capability.
• Technical support for tablet and powder formulation.

Distributors and regional manufacturers

Distributors can offer shorter lead times and local inventory but may have less control over manufacturing continuity. Regional producers may compete effectively where customers prioritize local qualification, lower freight costs, or dual sourcing.

Because product names and grade names vary by supplier, procurement teams should compare chemical and physical specifications rather than rely on the generic term "magnesium carbonate."

What regulatory standards apply to magnesium carbonate as an excipient?

Magnesium carbonate used in pharmaceuticals must comply with the applicable pharmacopoeial and national requirements for the target market. Common reference standards include:

• United States Pharmacopeia and National Formulary.
• European Pharmacopoeia.
• British Pharmacopoeia.
• Japanese Pharmacopoeia.
• Chinese Pharmacopoeia.
• Applicable food and pharmaceutical regulations in the importing country.

The active pharmaceutical ingredient and excipient status can differ by product. Magnesium carbonate can function as an active antacid or magnesium source in one product and as an inactive excipient in another. The regulatory pathway depends on the formulation, labeling, dosage, claims, and jurisdiction.

What is the FDA status of magnesium carbonate?

Magnesium carbonate does not have a conventional New Drug Application exclusivity position when used as an excipient. Its use in a finished drug depends on the product’s regulatory basis and the applicable FDA requirements.

The FDA Inactive Ingredient Database is a key reference for whether a substance has been used in approved drug products, including route and dosage-form information. Database presence does not create market exclusivity and does not guarantee acceptance at every concentration or in every dosage form (U.S. Food and Drug Administration, n.d.-a).

For over-the-counter antacid products, regulatory status may also depend on the applicable FDA monograph and product conditions. A company must distinguish between:

• Magnesium carbonate as a labeled active ingredient.
• Magnesium carbonate as an inactive formulation component.
• Magnesium carbonate used in a prescription product.
• Magnesium carbonate used in a dietary supplement.

These categories carry different documentation and labeling requirements.

What patents protect pharmaceutical magnesium carbonate?

The core compound is old, widely known, and not protected by a viable composition-of-matter patent. The commercial patent landscape is therefore narrow compared with pharmaceutical active ingredients.

Potentially relevant rights may cover:

• Particle-size distribution.
• Porosity or morphology.
• Surface treatment.
• Co-processing with another excipient.
• Controlled-release or gastric-retention formulations.
• Taste masking.
• Effervescent or chewable dosage forms.
• Manufacturing processes.
• Specific combinations with active ingredients.
• Packaging or moisture-control systems.

A patent directed to a finished formulation may protect a product containing magnesium carbonate without protecting magnesium carbonate itself. Freedom-to-operate analysis must therefore be claim-specific and jurisdiction-specific.

Are there Orange Book listings for magnesium carbonate?

Magnesium carbonate itself is not expected to have an Orange Book listing as a standalone excipient. The FDA Orange Book lists approved drug products and related patent or exclusivity information, not a general registry of excipient rights (U.S. Food and Drug Administration, n.d.-b).

A finished product containing magnesium carbonate could have listed patents directed to its active ingredient, formulation, delivery system, or method of use. Those rights would belong to the finished product, not to magnesium carbonate as a raw material.

Do Paragraph IV challenges apply?

Paragraph IV litigation generally concerns an abbreviated new drug application challenging patents listed for a reference listed drug. It is not a normal pathway for challenging the commercial use of magnesium carbonate as an excipient.

A generic product containing magnesium carbonate could face Paragraph IV issues if the finished reference drug has Orange Book-listed patents. The dispute would ordinarily concern the drug product’s claims, formulation, or use, not the general availability of magnesium carbonate.

When does magnesium carbonate lose exclusivity?

Magnesium carbonate has no practical modern exclusivity loss date because the compound is long established and broadly available. There is no expected composition-of-matter cliff comparable to that of a patented small-molecule drug.

Exclusivity category	Magnesium carbonate position
Composition-of-matter patent	No meaningful current protection
Orange Book exclusivity	Not applicable to the excipient itself
New chemical entity exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Formulation patent	Possible for a specific finished product
Process patent	Possible but usually narrow
Trade-secret protection	Possible for manufacturing controls
Supplier qualification protection	Commercial, not statutory

The principal barrier to substitution is customer qualification, not patent exclusivity. A pharmaceutical manufacturer may need to repeat compatibility, stability, process-performance, and regulatory assessments before changing suppliers or grades.

What manufacturing and intellectual-property barriers affect supply?

Magnesium carbonate can be produced from magnesium-bearing minerals or magnesium-containing solutions. Commercial processes may involve precipitation, carbonation, drying, milling, classification, and packaging.

The manufacturing barriers are operational rather than fundamental:

• Raw-material purity.
• Control of hydration and carbonate composition.
• Particle-size consistency.
• Bulk-density control.
• Low microbial burden.
• Prevention of cross-contamination.
• Validation of drying and milling.
• Trace-metal control.
• Consistent packaging and storage.
• Change-control discipline.

The most defensible intellectual property is likely to relate to process parameters or engineered physical properties. Trade secrets may be more valuable than patents where the process is difficult to reverse engineer and the product is sold under a customer-specific specification.

A supplier’s ability to document the relationship between process conditions and tablet performance can create a practical switching barrier. That barrier is commercially significant even when patent protection is absent.

What formulation patents involve magnesium carbonate?

Formulation patents may use magnesium carbonate for technical reasons rather than as the central inventive concept. Examples include:

Antacid formulations

Claims may cover combinations of magnesium carbonate with calcium carbonate, magnesium hydroxide, aluminum hydroxide, alginates, or other gastric-acid neutralizers.

Chewable tablets

Magnesium carbonate can affect hardness, mouthfeel, chalkiness, disintegration, and compression. A patent may claim a specific particle-size distribution, sweetener system, lubricant combination, or flavoring system.

Effervescent products

Carbonate-based ingredients can participate in acid-base reactions with citric acid, tartaric acid, or other acids. Moisture control and reaction stability are key technical issues.

Mineral supplements

Claims may cover the ratio of magnesium to other minerals, dosage form, bioavailability, gastrointestinal tolerability, or combination with vitamins.

Modified-release and gastric-retention systems

A patent may use carbonate-containing materials to generate gas, alter buoyancy, control local pH, or modify residence time in the gastrointestinal tract.

These rights can affect a finished product launch even when the raw-material supplier has no enforceable rights over the compound.

What litigation affects magnesium carbonate?

There is no widely recognized, sector-defining patent litigation centered on magnesium carbonate as a standalone pharmaceutical excipient. Litigation risk is more likely to arise in four areas:

1. A branded finished drug containing magnesium carbonate.
2. A chewable or effervescent formulation.
3. A controlled-release or gastric-retention dosage form.
4. A supplier dispute involving specifications, contamination, labeling, or supply failure.

Generic entrants should search formulation and method-of-use patents associated with the finished reference product. They should not assume that the absence of magnesium carbonate compound patents eliminates product-level litigation risk.

How does magnesium carbonate compare with competing magnesium excipients?

Material	Main advantages	Main limitations
Magnesium carbonate	Low cost, established use, carbonate chemistry, useful powder properties	Chalkiness, variable density, limited differentiation
Magnesium oxide	High elemental magnesium content, broad availability	Poorer solubility and potential formulation limitations
Magnesium hydroxide	Established antacid use, predictable alkaline behavior	Different density, flow, and suspension behavior
Magnesium citrate	Often selected for supplement products and solubility profile	Higher cost and different hygroscopicity
Magnesium stearate	Lubricant, not a direct substitute for carbonate	Different functional role
Calcium carbonate	Low cost and strong antacid history	Not a magnesium source; different density and reactivity
Synthetic co-processed excipients	Tunable performance	Higher cost and more complex qualification

Substitution is not automatic. A change from magnesium carbonate to magnesium oxide or magnesium hydroxide can alter elemental magnesium content, pH, dissolution, tablet weight, hardness, disintegration, taste, and stability.

What generic entry risks exist for products containing magnesium carbonate?

Generic entry risk is usually high at the raw-material level and product-specific at the finished-drug level.

Raw-material level

Risk is high because:

• The compound is widely available.
• There is no practical compound patent barrier.
• Multiple grades can be sourced globally.
• Substitution between qualified suppliers is feasible.

Finished-product level

Risk depends on:

• Orange Book-listed patents.
• Formulation claims.
• Method-of-use claims.
• Dosage-form complexity.
• Product-specific regulatory exclusivity.
• Manufacturing know-how.
• Brand recognition and retail positioning.

For simple tablets, the main barriers are regulatory filing, bioequivalence where required, manufacturing economics, and distribution. For chewables, effervescents, suspensions, and modified-release products, formulation and process barriers can be higher.

What is the geographic outlook for magnesium carbonate supply?

Asia-Pacific is likely to remain the largest manufacturing and consumption region for magnesium compounds because of its pharmaceutical production base, mineral resources, and lower manufacturing costs. Europe and North America remain important for premium pharmaceutical grades, regulatory documentation, contract manufacturing, and high-value formulation development.

Region	Market characteristics
Asia-Pacific	Volume growth, broad manufacturing base, price competition
Europe	Strong compliance requirements and premium-grade demand
North America	OTC, supplements, generic drugs, and distributor-led supply
Latin America	Growing healthcare production and import dependence
Middle East and Africa	Smaller base, increasing reliance on imported excipients

Geographic supply risk depends on the source of magnesite or brine, conversion capacity, port access, energy prices, and the number of qualified manufacturing sites. A pharmaceutical customer may maintain dual sourcing even when industrial supply is abundant because regulatory change control makes emergency replacement difficult.

How should investors and procurement teams assess the segment?

The most relevant diligence questions are operational:

• Is the product manufactured under pharmaceutical-quality controls?
• Does the supplier hold the required pharmacopoeial grade?
• Are light and heavy grades produced consistently?
• Is the source mineral stable?
• Are elemental impurities controlled?
• Is there a validated second manufacturing site?
• Does the supplier support regulatory filings?
• Are changes to process, site, or raw materials controlled?
• Does the customer qualify the supplier for a specific dosage form?
• Is revenue exposed to spot purchases or contracted volume?

A supplier with a broad pharmaceutical excipient portfolio may generate better economics than a magnesium-carbonate-only producer. Cross-selling, warehousing, regulatory support, and customer qualification can matter more than the product’s nominal price.

Key Takeaways

• Magnesium carbonate is a mature pharmaceutical excipient and, in some products, an active antacid or magnesium source.
• No standalone audited global revenue figure is publicly available for pharmaceutical-grade magnesium carbonate.
• The segment likely has low-single-digit volume and revenue growth, with limited structural pricing power.
• Pharmaceutical-grade suppliers can earn premiums through compliance, consistency, particle engineering, documentation, and supply reliability.
• The compound itself has no meaningful modern composition-of-matter exclusivity.
• Orange Book listings and Paragraph IV disputes apply to finished drug products, not to magnesium carbonate as a generic excipient.
• Formulation, process, and method-of-use patents can still affect products containing magnesium carbonate.
• The main commercial barrier is qualification and regulatory continuity rather than patent protection.
• Magnesium oxide, magnesium hydroxide, magnesium citrate, and calcium carbonate are the principal functional alternatives, but substitution requires formulation reassessment.
• Geographic supply risk is driven by mineral access, processing capacity, energy costs, logistics, and the number of qualified sites.

FAQs About Pharmaceutical Magnesium Carbonate

Is magnesium carbonate approved for use in tablets?

Magnesium carbonate has established pharmaceutical and food uses, but acceptance depends on the specific grade, route, dosage form, concentration, and regulatory jurisdiction. FDA and pharmacopoeial documentation should be reviewed for the intended product.

Is pharmaceutical magnesium carbonate interchangeable between suppliers?

No. Chemical identity alone does not establish interchangeability. Bulk density, particle size, morphology, moisture, impurities, flow, compression performance, and microbiological quality can differ materially.

Does magnesium carbonate have a drug master file?

Some suppliers may maintain regulatory files or confidential manufacturing documentation, but a drug master file is supplier-specific and should not be assumed from the existence of a pharmacopoeial monograph.

Is magnesium carbonate suitable for direct compression?

It can be suitable in selected formulations, but performance depends on grade and particle engineering. Flow, compressibility, lubricant sensitivity, tablet hardness, and disintegration must be evaluated experimentally.

Can a pharmaceutical company manufacture magnesium carbonate without licensing a patent?

Generally, the basic compound is not subject to a practical composition patent barrier. A company must still assess process patents, formulation patents, regulatory requirements, quality standards, environmental controls, and third-party contractual restrictions.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.

2. International Pharmaceutical Excipients Council. (2020). Good manufacturing practices guide for pharmaceutical excipients. IPEC.

3. National Center for Biotechnology Information. (n.d.). PubChem compound summary: Magnesium carbonate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Magnesium-carbonate

4. U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-overview

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

7. U.S. Food and Drug Administration. (2022). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211